Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04614558 · ClinicalTrials.gov registry record · Phase 2
Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance
A Phase 2 study of Monoclonal Gammopathy, sponsored by Columbia University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 2
- Study locations
NCT04614558 is a Phase 2 study of Monoclonal Gammopathy that is actively recruiting participants, run by Columbia University. The registered enrollment target is 27 participants, below the 131-participant average among 3 other Monoclonal Gammopathy trials with a reported enrollment target (79% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT04614558, a Phase 2 study of Monoclonal Gammopathy, is actively recruiting participants, sponsored by Columbia University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means that the use of isatuximab in this study is considered 'investigational'.
Conditions Studied
Interventions
- DRUG Isatuximab
Study Locations (2)
Massachusetts
- Massachusetts General Hospital, Renal Associates Clinic - Boston
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2021-06-08 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04614558
The ClinicalTrials.gov registry entry for NCT04614558 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 131-participant average among 3 other Monoclonal Gammopathy trials with a reported enrollment target (79% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Monoclonal Gammopathy appearing as the primary indexed condition, and to 1 intervention - of which Isatuximab is the first listed.
NCT04614558 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04614558 about?
NCT04614558 is a clinical study titled "Isatuximab in Patients With Monoclonal Gammopathy of Renal Significance". The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with MGRS. Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treat MGRS. This means t...
What is the current status of trial NCT04614558?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2021-06-08. Estimated completion is 2026-06.
What conditions does trial NCT04614558 study?
This clinical trial studies the following conditions: Monoclonal Gammopathy.
What interventions are being tested in trial NCT04614558?
The interventions under investigation include: Isatuximab (DRUG).
Who is sponsoring clinical trial NCT04614558?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04614558 being conducted?
This trial has 2 study locations across Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Monoclonal Gammopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Pre-malignant States to Hematologic Malignancies in Firefighters
RECRUITING
-
Rifaximin in Patients With Monoclonal Gammopathy
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.